Cite
HARVARD Citation
Joura, E. et al. (2021). Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study. Vaccine. 39 (20), pp. 2800-2809. [Online].